Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C16H25NO2 |
| Molecular Weight | 263.3752 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CN(C)C[C@H](C1=CC=C(O)C=C1)C2(O)CCCCC2
InChI
InChIKey=KYYIDSXMWOZKMP-OAHLLOKOSA-N
InChI=1S/C16H25NO2/c1-17(2)12-15(13-6-8-14(18)9-7-13)16(19)10-4-3-5-11-16/h6-9,15,18-19H,3-5,10-12H2,1-2H3/t15-/m1/s1
| Molecular Formula | C16H25NO2 |
| Molecular Weight | 263.3752 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Desvenlafaxine extended release. | 2008 |
|
| An assessment of drug-drug interactions: the effect of desvenlafaxine and duloxetine on the pharmacokinetics of the CYP2D6 probe desipramine in healthy subjects. | 2008 Dec |
|
| Desvenlafaxine succinate for major depressive disorder. | 2008 Jul |
|
| Efficacy, safety, and tolerability of desvenlafaxine 50 mg/day and 100 mg/day in outpatients with major depressive disorder. | 2008 Jul |
|
| Effect of desvenlafaxine on the cytochrome P450 2D6 enzyme system. | 2008 Nov |
|
| Desvenlafaxine: another "me too" drug? | 2008 Oct |
|
| Efficacy, safety, and tolerability of fixed-dose desvenlafaxine 50 and 100 mg/day for major depressive disorder in a placebo-controlled trial. | 2008 Sep |
|
| An integrated analysis of the safety and tolerability of desvenlafaxine compared with placebo in the treatment of major depressive disorder. | 2009 Apr |
|
| A double-blind, randomly assigned, placebo-controlled study of desvenlafaxine efficacy and safety for the treatment of vasomotor symptoms associated with menopause. | 2009 Feb |
|
| The effects of desvenlafaxine and paroxetine on the pharmacokinetics of the cytochrome P450 2D6 substrate desipramine in healthy adults. | 2009 Feb |
|
| Desvenlafaxine, a serotonin-norepinephrine uptake inhibitor for major depressive disorder, neuropathic pain and the vasomotor symptoms associated with menopause. | 2009 Jan |
|
| Preliminary data concerning the reliability and psychometric properties of the Greek translation of the 20-item Subjective Well-Being Under Neuroleptic Treatment Scale (SWN-20). | 2009 Jan 21 |
|
| Use of antidepressants for management of hot flashes. | 2009 Nov |
|
| Discontinuation symptoms and taper/poststudy-emergent adverse events with desvenlafaxine treatment for major depressive disorder. | 2009 Nov |
|
| Desvenlafaxine: application withdrawal. Desvenlafaxine: withdrawal of marketing application for depression also. | 2009 Oct |
|
| Desvenlafaxine and weight change in major depressive disorder. | 2010 |
|
| Optimal management of perimenopausal depression. | 2010 Aug 9 |
|
| Desvenlafaxine succinate: a newer antidepressant for the treatment of depression and somatic symptoms. | 2010 Jan |
Patents
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 01:34:38 GMT 2023
by
admin
on
Sat Dec 16 01:34:38 GMT 2023
|
| Record UNII |
189BFR45S0
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
9816723
Created by
admin on Sat Dec 16 01:34:38 GMT 2023 , Edited by admin on Sat Dec 16 01:34:38 GMT 2023
|
PRIMARY | |||
|
142761-12-4
Created by
admin on Sat Dec 16 01:34:38 GMT 2023 , Edited by admin on Sat Dec 16 01:34:38 GMT 2023
|
PRIMARY | |||
|
189BFR45S0
Created by
admin on Sat Dec 16 01:34:38 GMT 2023 , Edited by admin on Sat Dec 16 01:34:38 GMT 2023
|
PRIMARY | |||
|
273749-38-5
Created by
admin on Sat Dec 16 01:34:38 GMT 2023 , Edited by admin on Sat Dec 16 01:34:38 GMT 2023
|
SUPERSEDED |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
RACEMATE -> ENANTIOMER |
